# Nijmegen Antihypertensive Management Improvement Study

> **NCT00457483** · PHASE4 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 120 (actual)

## Conditions studied

- Primary Hypertension

## Interventions

- **DRUG:** hydrochlorothiazide
- **DRUG:** valsartan, 80 mg once-a-day

## Key facts

- **NCT ID:** NCT00457483
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2010-12
- **Final completion:** 2011-03
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2012-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00457483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00457483, "Nijmegen Antihypertensive Management Improvement Study". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT00457483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*